comparemela.com
Home
Live Updates
Upadacitinib Demonstrates Higher Rates of Adverse Events Compared with Adalimumab in PsA : comparemela.com
Upadacitinib Demonstrates Higher Rates of Adverse Events Compared with Adalimumab in PsA
Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.
Related Keywords
Berlin ,
Germany ,
Researchgate Gerdr Burmester ,
Gerdr Burmester ,
,
University Hospital ,
Department Of Rheumatology ,
Clinical Immunology ,
comparemela.com © 2020. All Rights Reserved.